TY - JOUR AU - Gehan, E. A. PY - 1961 DA - 1961// TI - The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent JO - Journal of Chronic Diseases VL - 13 UR - https://doi.org/10.1016/0021-9681(61)90060-1 DO - 10.1016/0021-9681(61)90060-1 ID - Gehan1961 ER - TY - JOUR AU - Fleming, T. R. PY - 1982 DA - 1982// TI - One sample multiple testing procedure for phase II clinical trials JO - Biometrics VL - 38 UR - https://doi.org/10.2307/2530297 DO - 10.2307/2530297 ID - Fleming1982 ER - TY - JOUR AU - Chang, M. N. AU - Therneau, T. M. AU - Wieand, H. S. AU - Cha, S. S. PY - 1987 DA - 1987// TI - Designs for group sequential phase II clinical trials JO - Biometrics VL - 43 UR - https://doi.org/10.2307/2531540 DO - 10.2307/2531540 ID - Chang1987 ER - TY - JOUR AU - Simon, R. PY - 1989 DA - 1989// TI - Optimal two-stage designs for phase II clinical trials JO - Controlled Clinical Trials VL - 10 UR - https://doi.org/10.1016/0197-2456(89)90015-9 DO - 10.1016/0197-2456(89)90015-9 ID - Simon1989 ER - TY - JOUR AU - Green, S. J. AU - Dahlberg, S. PY - 1992 DA - 1992// TI - Planned versus attained design in phase II clinical trials JO - Statistics in Medicine VL - 11 UR - https://doi.org/10.1002/sim.4780110703 DO - 10.1002/sim.4780110703 ID - Green1992 ER - TY - JOUR AU - Thall, P. F. AU - Richard, S. i. m. o. n. PY - 1994 DA - 1994// TI - Practical Bayesian guidelines for phase IIB clinical trials JO - Biometrics VL - 50 UR - https://doi.org/10.2307/2533377 DO - 10.2307/2533377 ID - Thall1994 ER - TY - JOUR AU - Chen, T. T. PY - 1997 DA - 1997// TI - Optimal three-stage designs for phase II cancer clinical trials JO - Statistics in Medicine VL - 16 UR - https://doi.org/3.0.CO;2-1 DO - 3.0.CO;2-1 ID - Chen1997 ER - TY - JOUR AU - Heitjan, D. F. PY - 1997 DA - 1997// TI - Bayesian interim analysis of phase II cancer clinical trials JO - Statistics in Medicine VL - 16 UR - https://doi.org/3.0.CO;2-E DO - 3.0.CO;2-E ID - Heitjan1997 ER - TY - JOUR AU - Herndon, J. E. PY - 1998 DA - 1998// TI - A design alternative for two-stage, phase II, multicenter cancer clinical trials JO - Controlled Clinical Trials VL - 19 UR - https://doi.org/10.1016/S0197-2456(98)00012-9 DO - 10.1016/S0197-2456(98)00012-9 ID - Herndon1998 ER - TY - JOUR AU - Chen, T. T. AU - Ng, T. -. H. PY - 1998 DA - 1998// TI - Optimal flexible designs in phase II clinical trials JO - Statistics in Medicine VL - 17 UR - https://doi.org/3.0.CO;2-X DO - 3.0.CO;2-X ID - Chen1998 ER - TY - JOUR AU - Colton, T. AU - McPherson, K. PY - 1976 DA - 1976// TI - Two-stage plans compared with fixed-sample-size and Wald SPRT plans JO - J Am Stat Assoc VL - 71 UR - https://doi.org/10.1080/01621459.1976.10481481 DO - 10.1080/01621459.1976.10481481 ID - Colton1976 ER - TY - JOUR AU - Landis, S. H. AU - Murray, T. AU - Bolden, S. AU - Wingo, P. A. PY - 1998 DA - 1998// TI - Cancer Statistics, 1998 JO - CA: A Cancer Journal for Clinicians VL - 48 ID - Landis1998 ER - TY - JOUR AU - Lawrence, T. PY - 1995 DA - 1995// TI - Gemcitabine as a radiation sensitizer JO - Sem Oncol VL - 22 ID - Lawrence1995 ER - TY - JOUR AU - Casper, E. S. AU - Green, M. R. AU - Kelsen, D. P. AU - Heelan, R. T. AU - Brown, T. D. AU - Flombaum, C. D. AU - Trochanowski, B. AU - Tarassoff, P. G. PY - 1994 DA - 1994// TI - Phase II trial of gemcitabine (2'2'-difluoro-2'-deoxycytidine) in patients with adenocarcinoma of the pancreas JO - Investigational New Drugs VL - 12 UR - https://doi.org/10.1007/BF00873232 DO - 10.1007/BF00873232 ID - Casper1994 ER - TY - JOUR AU - Burris, H. A. AU - Moore, M. J. AU - Andersen, J. AU - Green, M. R. AU - Rothenberg, M. L. AU - Modiano, M. R. AU - Cripps, M. C. AU - Portenoy, R. K. AU - Storniolo, A. M. AU - Tarassoff, R. AU - Nelson, R. AU - Dorr, F. A. AU - Stephens, C. D. AU - Von Hoff, D. D. PY - 1997 DA - 1997// TI - Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial JO - J Clin Oncol VL - 15 ID - Burris1997 ER - TY - JOUR AU - Blackstock, A. W. AU - Bernard, S. A. PY - 1999 DA - 1999// TI - Twice weekly gemcitabine and concurrent radiation: laboratory studies supporting phase I clinical trials in pancreatic cancer JO - Can Conf VL - 3 ID - Blackstock1999 ER - TY - JOUR AU - Kaplan, E. L. AU - Meier, P. PY - 1958 DA - 1958// TI - Nonparametric estimation from incomplete observations JO - J Am Stat Assoc VL - 53 UR - https://doi.org/10.1080/01621459.1958.10501452 DO - 10.1080/01621459.1958.10501452 ID - Kaplan1958 ER - TY - JOUR AU - Nelson, W. PY - 1969 DA - 1969// TI - Hazard plotting for incomplete failure data JO - J Quality Technology VL - 1 ID - Nelson1969 ER - TY - CHAP AU - Jennison, C. AU - Turnbull, B. W. PY - 2000 DA - 2000// TI - Group Sequential Designs with Applications to Clinical Trials BT - Boca Raton, Chapman & Hall/CRC ID - Jennison2000 ER - TY - JOUR AU - Lan, K. K. G. AU - DeMets, D. L. PY - 1983 DA - 1983// TI - Discrete sequential boundaries for clinical trials JO - Biometrika VL - 70 UR - https://doi.org/10.2307/2336502 DO - 10.2307/2336502 ID - Lan1983 ER - TY - JOUR AU - Lin, D. Y. AU - Shen, L. AU - Ying, Z. AU - Breslow, N. E. PY - 1996 DA - 1996// TI - Group sequential designs for monitoring survival probabilities JO - Biometrics VL - 52 UR - https://doi.org/10.2307/2533064 DO - 10.2307/2533064 ID - Lin1996 ER - TY - JOUR AU - Donnely, T. G. PY - 1973 DA - 1973// TI - Algorithm 462 – Bivariate normal distribution [S15] JO - Comm ACM VL - 16 UR - https://doi.org/10.1145/362375.362414 DO - 10.1145/362375.362414 ID - Donnely1973 ER - TY - CHAP AU - Brent, R. PY - 1973 DA - 1973// TI - Algorithms for Minimization without Derivatives BT - Englewood Cliffs, Prentice Hall ID - Brent1973 ER - TY - JOUR AU - Follmann, D. A. AU - Albert, P. S. PY - 1999 DA - 1999// TI - Bayesian monitoring of event rates with censored data JO - Biometrics VL - 55 UR - https://doi.org/10.1111/j.0006-341X.1999.00603.x DO - 10.1111/j.0006-341X.1999.00603.x ID - Follmann1999 ER - TY - JOUR AU - Cheung, Y. K. AU - Thall, P. F. PY - 2002 DA - 2002// TI - Monitoring the rates of composite events with censored data in phase II clinical trials JO - Biometrics VL - 58 UR - https://doi.org/10.1111/j.0006-341X.2002.00089.x DO - 10.1111/j.0006-341X.2002.00089.x ID - Cheung2002 ER - TY - JOUR AU - Case, L. D. AU - Morgan, T. M. PY - 2001 DA - 2001// TI - Duration of accrual and follow-up for two-stage clinical trials JO - Lifetime Data Analysis VL - 7 UR - https://doi.org/10.1023/A:1009621009283 DO - 10.1023/A:1009621009283 ID - Case2001 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/3/6/prepub UR - http://www.biomedcentral.com/1471-2288/3/6/prepub ID - ref27 ER -